Impact of pharmacotherapeutic education on medication adherence and adverse outcomes in patients with type 2 diabetes mellitus: a prospective, randomized study

• Published in: Croatian medical journal Vol. 59; no. 6; pp. 290 - 297
• Main Authors: Marušić, Srećko, Meliš, Petra, Lucijanić, Marko, Grgurević, Ivica, Turčić, Petra, Neto, Paulo Roque Obreli, Bilić-Ćurčić, Ines
• Format: Journal Article Paper
• Language: English
• Published: Croatia Sveuciliste U Zagrebu 01.12.2018; Medicinski fakultet Sveučilišta u Zagrebu, Medicinski fakultet Sveučilišta u Splitu, Medicinski fakultet Sveučilišta u Rijeci; Croatian Medical Schools
• Subjects: Aged; Analysis; Care and treatment; Clinical Science; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Diabetes therapy; Female; Health education; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Male; Medication Adherence; Middle Aged; Patient compliance; Patient education; Patient Education as Topic; Prospective Studies; Type 2 diabetes; Croatia
• ISSN: 0353-9504; 1332-8166
• DOI: 10.3325/cmj.2018.59.290

To evaluate the impact of pharmacotherapeutic education on 30-day post-discharge medication adherence and adverse outcomes in patients with type 2 diabetes mellitus (T2DM). The prospective, randomized, single-center study was conducted at the Medical Department of University Hospital Dubrava, Zagreb, between April and June 2018. One hundred and thirty adult patients with T2DM who were discharged to the community were randomly assigned to either the intervention or the control group. Both groups during the hospital stay received the usual diabetes education. The intervention group received additional individual pre-discharge pharmacotherapeutic education about the discharge prescriptions. Medication adherence and occurrence of adverse outcomes (adverse drug reactions, readmission, emergency department visits, and death) were assessed at the follow-up visit, 30 days after discharge. The number of adherent patients was significantly higher in the intervention group (57/64 [89.9%] vs 41/61 [67.2%]; χ2 test, P=0.003]. There was no significant difference between the groups in the number of patients who experienced adverse outcomes (31/64 [48.4%] vs 36/61 [59.0%]; χ2 test, P=0.236). However, higher frequencies of all adverse outcomes were consistently observed in the control group. Pharmacotherapeutic education of patients with T2DM can significantly improve 30-day post-discharge medication adherence, without a significant reduction in adverse clinical outcomes. ClinicalTrial.gov identification number: NCT03438162.